FDA considers pump classification

12/10/2012 | CardiovascularBusiness.com

In federal testimony on behalf of SCAI, Dr. George Vetrovec expressed support for use of the nonroller pump for left ventricular support and percutaneous coronary intervention. An FDA panel voted last week that nonroller type cardiopulmonary bypass blood pumps should remain Class III devices, meaning that if the FDA follows the recommendation, manufacturers will have to prepare premarket approval documents. Vetrovec said that could pose a hardship for small manufacturers and divert resources from innovation.

View Full Article in:

CardiovascularBusiness.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA